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Summary. To assess the current practice patterns in the diagnosis and treatment of 
male osteoporosis based on questionnaires. Questionnaires were presented and fi lled 
out by osteoporosis experts from Austria, Bulgaria, the Czech Republic, Hungary, Po-
land, Romania, Slovakia, Slovenia and Russia. The questions included focused on the 
proportion of male referrals to DXA, the main reasons for referral, the preferred mea-
surement sites and reference database, the defi nition of male osteoporosis, needed 
laboratory investigations, data on calcium and vitamin D supplementation as well as 
on treatment modalities and their reimbursement rate. Men comprised 5 to 10% of all 
DXA referrals. The main reasons for referral were low back pain and fractures. Most 
of the respondents used the International male reference database. The diagnosis of 
osteoporosis was based mainly on a T-score below -2.5 after the age of 50, but a 
few respondents added fractures as a necessary condition. Only 1/3 of men visiting 
DXA sites are expected to have normal BMD. A consensus for the use of laboratory 
investigations in male osteoporosis is practically lacking. Treatment modalities include 
alendronate, risedronate, zoledronate, denosumab, rhPTH and strontium (with some 
restrictions for the latter three). Data on treatment adherence and persistence are gen-
erally lacking except for Austria, Romania and Slovakia. The levels of reimbursement 
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INTRODUCTION
Osteoporosis in men evolves to a critical prob-lem in the health care systems of developed countries. We analyzed clinical practice pat-
terns in men with osteoporosis in the countries from 
Central and Eastern Europe (CEE) and to identify 
problems connected with the referral, diagnosis and 
treatment of osteoporosis in men.
Aging in men, as in women, is associated with bone 
loss and osteoporotic fractures. Osteoporosis in el-
derly men evolves to a critical problem in the health 
care systems of all developed countries. The inci-
dence of fractures in men seems bimodal with a peak 
in adolescence and mid-adulthood, a lower incidence 
between 40 and 60 years, and a dramatic increase 
after the age of 70 year [1-4]. The consequences of 
fractures, especially in the hip region in men seem as 
serious as in women, but elderly men are more likely 
to die from fractures than do women [5, 65]. 
A large body of evidence is available on risk factors 
and primary and secondary prevention of fractures in 
men [7, 8]. Dual-energy X-ray absorptiometry (DXA) 
is the cornerstone in measuring bone mass and frac-
ture risk in men. However, still there are controver-
sies on the reference base that should be used in 
calculating T- and Z-scores in men [9-11]. DXA is 
cost-effective in both fracture risk prediction with or 
without implementing the FRAX-calculator, and in 
universal prevention strategies [12-15]. Most of the 
drugs used in the treatment of postmenopausal os-
teoporosis have proven effi cacious and cost-effective 
in men also [16-23].
A compendium of country-specifi c reports on os-
teoporosis in the European Union was published in 
2013 [24]. The presented data included some per-
spectives and fi gures on male osteoporosis in the 
reporting countries [25-32]. However, the number of 
publications on male osteoporosis coming from the 
countries in Central and Eastern Europe (CEE) is still 
limited [33-39]. More information is needed to assess 
the patterns in the diagnosis and treatment of osteo-
porosis in men in those countries. 
The aim of the present study was to assess the cur-
rent practice patterns in the diagnosis and treatment 
of male osteoporosis based on questionnaires fi lled 
out by osteoporosis experts from Austria, Bulgaria, 
the Czech Republic, Hungary, Poland, Romania, Slo-
vakia, Slovenia and Russia.
MATERIAL AND METHODS
This study was an expert-based survey of clinical 
practice patterns in male osteoporosis in the follow-
ing CEE countries: Austria, Bulgaria, Czech Repub-
lic, Hungary, Poland, Romania, Slovakia, Slovenia 
and Russia. Representatives of these countries par-
ticipated in the annual meetings of the CEE Osteo-
porosis Summit. The 7th CEE Summit Conference 
on Osteoporosis took place on December 5th, 2015, 
in Sofi a (Bulgaria). Participants are among the lead-
ing medical specialists in the fi eld of metabolic bone 
diseases from the above listed and other countries 
from the region.
The survey was based on a questionnaire address-
ing the key points in the epidemiology, diagnosis 
and treatment of male osteoporosis in the afore-
mentioned countries. The questionnaire is attached 
below as Appendix 1. It addressed questions about 
the proportion of men visiting the Osteoporosis units 
compared with women; the prevalence of low bone 
density and major fractures; the densitometric and 
other diagnostic criteria for osteoporosis; the male-
specifi c laboratory investigations, the basic calcium 
and vitamin D supplementation and the treatment 
and reimbursement modalities in the different partici-
pating countries.
The respondents were members of the CEE Osteo-
porosis Summit Working Group. Whenever possible, 
offi cial or published data were used as reference. 
However, the survey is based mainly on expert opin-
ions and does not represent offi cial statements of the 
respective medical societies or authorities in the dif-
ferent countries.
vary a lot across countries. Osteoporosis in men is an under-recognized problem in 
CEE countries, leading to a tremendous gap in the diagnosis and treatment.
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Appendix 1. Male Osteoporosis – Questionnaire
1. What is the proportion of men versus women re-
ferred for DXA examinations?
2. What is the main reason for referral of men for
BMD testing?
3. What is the preferred measurement site in men –
lumbar spine or proximal femur (total hip or neck)?
4. What reference database is implemented for the
calculation of T-scores – male or female?
5. What are the criteria for male osteoporosis ac-
cording to your local guidelines?
6. What proportion of all studied men have osteo-
porosis/low bone mass at the spine or hip?
7. What proportion of all studied men have previ-
ous low trauma fractures (hip, vertebrae, humer-
us, wrist) – if known?
8. Is serum testosterone measurement part of the
routine lab check-up?
9. Is 24-hr urine calcium part of the routine lab
check-up?
10. What is the proportion of men with diagnosed
osteoporosis or fractures receiving calcium sup-
plements – if known?
11. What is the proportion of men with diagnosed
osteoporosis or fractures receiving vitamin D – if
known?
12. Which antiosteoporotic drug modalities exist for
men with osteoporosis in your country?
13. What is the persistence and adherence to the
treatment in men, if known?
14. Are antiresorptive and anabolic treatments reim-
bursed for osteoporosis in men?
RESULTS
All countries participated in the survey. Each coun-
try provided one set of data except for Bulgaria (2 
sets) and Russia (4 sets). The answers to the 1st part 
of questions (1 through 7) are listed in Table 1, and 
those to the 2nd part (8 through 14) – in Table 2.
Most of the experts agreed that men comprised 
around 5 to 10% of all DXA referrals. The main 
reasons for referral were low back pain and frac-
tures but some countries indicated secondary 
osteoporosis as the most important option (like 
Hungary, Slovakia and Slovenia). Most of the re-
spondents used the International Male Reference 
database, but some used a female database (Slo-
vakia), while others combined female and male 
databases (Hungary). The diagnosis of osteopo-
rosis was based mainly on a T-score below -2.5 
after the age of 50, but some respondents added 
fractures as a necessary condition (like Russia). 
It is interesting to note that around 20-30% of all 
men receiving DXA scans had osteoporosis at the 
spine and a lower percentage – at the proximal 
femur. There were big differences between coun-
tries and in some of them data were not detailed 
enough. Almost the same proportion of men had 
low bone mass, which precluded that only one 
third of men visiting DXA sites are expected to 
have normal BMD. This is far less than the re-
spective figures in women.
Concerning specifi c laboratory investigations in 
male osteoporosis, measurement of serum testos-
terone is done routinely by two thirds of the respon-
dents; the same was true for 24-hr urine calcium. 
Therefore, consensus for the use of laboratory 
investigations in male osteoporosis is practically 
lacking. 
Our data show that the diagnosis of osteoporosis 
in men led to basic calcium supplement in a very 
different proportion – from 0-10% (Bulgaria) to 90% 
(in the Czech Republic). Vitamin D supplements 
are prescribed to a somewhat greater proportion 
of the osteoporosis male patients, though not to all 
of them.
Osteoporosis treatment modalities include three 
bisphosphonates (alendronate, risedronate, zole-
dronate), denosumab, rhPTH and strontium ranelate 
(with some restrictions for the latter three). However, 
data on treatment adherence and persistence are 
generally lacking except for Romania and Slova-
kia. The levels of reimbursement vary a lot across 
countries and are an important barrier to initiating 
and continuing the optimal anti-resorptive or bone-
building agent.
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DISCUSSION
Male osteoporosis is a serious problem of the ag-
ing population which is often underdiagnosed and 
under-treated and related to the country-specifi c life 
expectancy. This survey tried to clarify the common 
clinical practice patterns concerning osteoporosis in 
men. The survey was based on leading expert opin-
ion and might not universally refl ect the situation in 
the respective countries. 
The fi rst conclusion from our data could be that men 
rarely visit DXA facilities, but have osteoporosis/low 
bone mass even more frequently than women in the 
same situation. Keeping in mind that the prevalence 
of low bone mass and fractures in men is three to 
four times lower than that in women, it is surprising 
that men comprise only 5 to 10 percent of all DXA 
examinations. Our data show that osteoporosis in 
men is most severely underdiagnosed. There was an 
enormous variability in the prevalence of spine and 
hip fractures in the studied men – from small per-
centages (<10%) like in Romania to almost 50% in 
Bulgaria and the Czech Republic. These data refl ect 
the differences in the criteria for referrals for a BMD 
measurement among the males, e.g. low back pain 
in Romania and clinical fractures in Bulgaria and the 
Czech Republic. Our survey showed that practically 
there are no robust data on the epidemiology of frac-
tures in men in CEE. 
Our survey was not aimed at defi ning a true preva-
lence of osteoporosis and fractures in men, but ap-
proximated data could be found in the Report on Os-
teoporosis in the European countries by the IOF and 
the EFPIA (see Table 3 below) [23-31].
Table 3. Data on the prevalence of osteoporosis and fractures in men, as presented in the report of the Inter-
national Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associa-
tions (EFPIA) [23-31]
% men with osteopo-
rosisa
% men with prevalent 
hip fracturesb
% men with prevalent clinical 
vertebral fracturesb Treatment gap
Austria 6.51% 1.57% 1.86% 52.0%
Bulgaria 6.42% 0.89% 0.93% 98.0%
Czech Republic 6.03% 1.05% 1.25% 88.0%
Hungary 6.17% 0.96% 1.02% 41.0%
Poland 5.82% 0.70% 0.77% 91.0%
Romania 6.17% 0.81% 0.94% 94.0%
Slovakia 5.66% 1.22% 1.49% 78.0%
Slovenia 5.99% 0.99% 1.23% 63.0%
aOsteoporosis is defi ned as femoral neck T-score ≤ -2.5 SD using female-derived reference ranges
bDerived from the total number of men with prevalent fractures divided by the total number of men in the same age group 
Table 3 shows that although osteoporotic fractures 
are uncommon in the general male population, they 
are very common in men seeking DXA scanning 
partly due to the fact that back pain and fractures 
are one of the major indications for referring men to 
DXA. This means that fractures should be actively 
sought in every man visiting an Osteoporosis or Bone 
Metabolic Unit. Data from the literature clearly show 
that compliance with osteoporosis treatment is the 
cornerstone of fracture prevention [40]. Compliance 
is a function of a number of factors, medication reim-
bursement being one of the major. The level of reim-
bursement of osteoporosis drugs for men is lowest 
in Bulgaria and Romania and highly variable among 
countries. This fact might explain the big treatment 
gap as indicated in the report by the IOF and EFPIA. 
It is found to be unacceptably wide in Bulgaria and 
Romania (> 90%), but still very wide in the remaining 
countries.
The major limitation of our survey is that it was based 
on expert opinion. Published data on male osteopo-
rosis in the CEE countries are very scarce and com-
pletely insuffi cient. The results could not be general-
ized as specifi c fi gures. The major advantage of this 
survey is that it shed some light on the diagnosis and 
treatment of male osteoporosis in the respective CEE 
countries and allowed to highlight hot spots for future 
research and administrative improvements.
CONCLUSIONS
Male osteoporosis is an underestimated problem. 
Men should be educated about the risk of osteopo-
rosis and referred to specialized units whenever pos-
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sible and needed. There is need for standardization 
of diagnostic procedures and criteria among Euro-
pean countries similarly to the recommendations by 
the IOF and ESCEO primarily created for postmeno-
pausal women only [42]. The treatment gap in males 
is unacceptably wide and the level of reimbursement 
– rather low. The medical societies must support
health care administrative organs to change regula-
tions to allow easier access of men to diagnosis and
treatment of osteoporosis and fractures.
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